STOCK TITAN

Madrigal Pharmaceuticals Announces Participation at Three Upcoming Investor Conferences

(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Tags
conferences

Madrigal Pharmaceuticals (NASDAQ: MDGL) will participate in fireside chats at three upcoming investor conferences, beginning on November 17, 2026.

The Jefferies Global Healthcare Conference in London chat is November 17 at 10:30 a.m. GMT (5:30 a.m. ET). The Evercore Healthcare Conference chat is December 1 at 8:20 a.m. ET, followed by Piper Sandler on December 2 at 8:30 a.m. ET. Live webcasts will be available through Madrigal’s Investor Relations Events page.

Loading...
Loading translation...

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

CONSHOHOCKEN, Pa., Nov. 13, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) today announced that the company will participate in fireside chats at three upcoming investor conferences:

The fireside chats will be webcast live and can be accessed by visiting Madrigal’s Investor Relations Events page.

Jefferies Global Healthcare Conference in London
Tuesday, Nov. 17, 2026 at 10:30 A.M. GMT (5:30 A.M. ET)

9th Annual Evercore Healthcare Conference
Tuesday, Dec. 1, 2026 at 8:20 A.M. ET

Piper Sandler 38th Annual Healthcare Conference
Wednesday, Dec. 2, 2026 at 8:30 A.M. ET

About Madrigal
Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. Madrigal’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of MASH. Rezdiffra was the first medication approved by both the FDA and European Commission for the treatment of MASH with moderate to advanced fibrosis (F2 to F3). An ongoing Phase 3 outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (F4c). For more information, visit www.madrigalpharma.com and follow us on LinkedIn.

Investor Contact
Tina Ventura, IR@madrigalpharma.com

Media Contact
Christopher Frates, media@madrigalpharma.com


Keep reading